Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

In a presentation at the Society for Neuroscience 2021 meeting, Ben Land, Ph.D., research assistant professor at the University of Washington’s Department of Pharmacology, reported additional positive data from an...

November 8, 2021

Developments

TransMedics posts positive results from randomized OCS DCD heart trial

TransMedics Group (NASDAQ:TMDX) reported positive topline results from its OCS donors after circulatory death (DCD) heart trial. The OCS DCD heart trial was designed as the first and only randomized trial to compare...

November 4, 2021

Developments

Activ Surgical completes first In-human study of surgical intelligence and sensing platform

Closely held Activ Surgical, a digital surgery pioneer, completed of its first-in-human surgery clinical trial utilizing the company’s technology-as-a-service bundle: the ActivInsights augment reality (AR)-based...

November 3, 2021

Developments

Clene fails to meet endpoints in Phase 2 RESCUE-ALS clinical trial

Top-line data from Clene’s RESCUE-ALS, a Phase 2 clinical trial evaluating CNM-Au8 as a disease modifying treatment for people with early amyotrophic lateral sclerosis (ALS), failed to meet the primary or...

November 2, 2021

Developments

FDA grants Sio Gene fast track for gene therapy for GM2 gangliosidosis

Sio Gene Therapies (NASDAQ:SIOX) received fast track designation for AXO-AAV-GM2, an investigational gene therapy for the treatment of early infantile, late infantile, and juvenile-onset Tay-Sachs and Sandhoff disease...

November 1, 2021

Developments

South Africa clears Phase 1 trial for Oramed oral COVID-19 vaccine

Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) majority-owned subsidiary, Oravax Medical, received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in...

October 29, 2021

Developments

POINT Biopharma, Kinectrics in Yb-176 supply agreement for NA production of n.c.a. Lu-177

Radiopharmaceuticals developer, POINT Biopharma Global (NASDAQ:PNT), and Kinectrics entered into a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a...

October 29, 2021

Developments

Kezar doses first patient in advanced solid tumor malignancies study

Kezar Life Sciences (NASDAQ:KZR) dosed the first patient in a Phase 1 clinical trial evaluating KZR-261, a broad-spectrum, anti-tumor agent that acts through direct interaction and inhibition of the Sec61 translocon...

October 27, 2021

Developments

Altamira, Wellesta in LOU to distribute Bentrio in 6 key Asian markets

Altamira Therapeutics (NASDAQ:CYTO) signed a letter of understanding (LOU) with Singapore’s Wellesta Holdings for the marketing and distribution of Bentrio, its nasal spray for protection against airborne viruses and...

October 25, 2021

Developments

111, Inc., Chugai Pharma China in strategic partnership to accelerate chronic disease management

111, Inc. (NASDAQ:YI) entered into a strategic cooperation agreement with Chugai Pharma China. The agreement would allow the two companies to build a “Healthy China” by establishing a “SMART Healthcare...

October 25, 2021

Developments

Titan Pharma receives funding from Gates Foundation for combination HIV therapeutic and contraceptive implant for women in developing countries

Titan Pharmaceuticals (NASDAQ:TTNP) has received funding from the Bill & Melinda Gates Foundation to support its ability to deliver a human immunodeficiency virus (HIV) preventative therapeutic and a contraceptive...

October 25, 2021

Developments

PharmaJet, WHO, Gates Foundation in Somalia polio vaccination campaign

Closely held PharmaJet’s Tropis intradermal needle-free injection system is being used in a campaign in Somalia, delivering inactivated polio vaccine to more than 110,000 children. The purpose of the campaign, funded in...

October 21, 2021

Developments

HashCo launches premium craft-style hash products

The Hash Corporation (CSE:REZN) launched its suite of specialty hash products – Gold Seal Hash and Cold Tumbled Resin – to licensed retailers via the Ontario Cannabis Store. Both products are manufactured by a...

October 21, 2021

Developments

Sio Gene presents positive interim Phase 1/2 data in GM1 gangliosidosis

Sio Gene Therapies (NASDAQ:SIOX) presented positive interim data from its ongoing Phase 1/2 study of AXO-AAV-GM1, its adeno-associated viral vector 9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

October 21, 2021

Developments

FDA clears Cognetivity’s cognitive assessment test

The FDA approved Cognetivity Neurosciences’ (CSE:CGN; OTCQB:CGNSF; FWB:1UB) 510(k) submission of its Integrated Cognitive Assessment (ICA) as a Class 2 exempt medical device, clearing the way for a commercial rollout...

October 20, 2021

Developments

NeoTX enrolls first patient in Phase 2a NAP trial in NSCLC

Closely held NeoTX Therapeutics of Israel enrolled the first patient in its Phase 2a clinical trial of naptumomab estafenatox (NAP), its lead tumor targeted superantigen candidate, in combination with docetaxel in...

October 20, 2021

Developments

111, Inc. executive chairman Dr. YU Gang receives 2021 China Artificial Intelligence Award

Dr. YU Gang, co-founder and executive chairman of 111, Inc. (NASDAQ:YI), received the 2021 China AI Golden Goose Award for outstanding achievements. In accepting the award at the 2021 China Artificial Intelligence...

October 19, 2021

Developments

Entasis posts positive topline Phase 3 results with SUR-DUR

Entasis Therapeutics (NASDAQ:ETTX) announced positive topline results from its ATTACK global Phase 3 trial evaluating the safety and efficacy of SUL-DUR (sulbactam-durlobactam) versus colistin in patients with...

October 19, 2021

Developments

111, Inc. selected to 2021 China Top 20 Internet Healthcare Companies list

111, Inc. (NASDAQ:YI) was selected as one of the 2021 Top 20 Internet Healthcare Enterprises in China for its innovation and promotion in the internet+healthcare field and its transformative platform serving the...

October 15, 2021

Developments

VistaGen expands PH948 in Phase 2a trial for adjustment disorder

VistaGen Therapeutics (NASDAQ:VTGN) initiated a Phase 2a clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety...

October 14, 2021

Developments

FDA accepts Altamira 510(k) application for Bentrio

Altamira Therapeutics’ (NASDAQ:CYTO) 510(k) application for premarket clearance for its Bentrio nasal spray for protection against airborne allergens was accepted for review by the FDA. The application now moves to a...

October 14, 2021

Developments

Labster to acquire UbiSim in virtual reality training expansion

Labster, a leading platform for virtual labs and interactive science based in Denmark, signed a definitive agreement to acquire UbiSim, a virtual reality training platform for nursing, in a move to further transform...

October 14, 2021

Subscribe